BJH - volume 9, issue Multiple Myeloma Special Edition, december 2018
M. Vercruyssen MD, L. Vrancken , J. Caers MD, PhD
Multiple Myeloma (MM) and other plasma cell malignancies initially present as an asymptomatic precursor state, known as monoclonal gammopathy of undetermined significance (MGUS). When confronted to a monoclonal protein in blood or urine tests, physicians should first exclude the presence of a treatment-requiring MM. They should be aware that there are two benign precursor states, that do not require anti-myeloma treatment. Both MGUS and Smoldering Multiple Myeloma (SMM) need an initial visit by a haematologist, with further follow-up tailored to the individual patient and disease characteristics. In the current article we describe both entities, discuss their monitoring and resume the latest publications in their field.
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
L. Delens , G. Ehx , L. Vrancken , G. Fransolet , C. Grégoire MD, M. Hannon , S. Dubois , C. Daulne , Y. Beguin MD, PhD, prof. F. Baron , S. Servais MD, PhD
BJH - volume 7, issue Abstract Book BHS, january 2016
L. Delens , S. Servais MD, PhD, L. Vrancken , G. Ehx , G. Fransolet , M. Hannon , S. Dubois , C. Daulne , Y. Beguin MD, PhD, prof. F. Baron
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
